The European Medicines Agency will review drugs similar to Vioxx, withdrawn by Merck due to increased stroke and heart attack risks.
Pfizer's Celebrex data surpasses Vioxx's, while Bextra poses potential dangers.
Lawsuits against Merck in Canada and the US highlight Vioxx's health risks.
Merck faces financial losses and legal battles over Vioxx's withdrawal.
Concerns about cardiovascular issues with Vioxx and similar drugs persist.
The New England Journal of Medicine suggests other drugs may also raise heart and stroke risks.
Vioxx lawsuits are expected to increase, challenging victims to prove drug-related health problems.
